Affimed Announces Two New Appointments to Its Supervisory Board
August 05 2020 - 6:30AM
Heidelberg, Germany, August 5,
2020 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage
immuno-oncology company committed to giving patients back their
innate ability to fight cancer, today announced the appointments of
Dr. Annalisa Jenkins and Mr. Harry Welten to its Supervisory
Board. Both these appointments were approved during the
Annual General Meeting of Shareholders which took place on August
4, 2020.
“Affimed is pleased to welcome Annalisa and
Harry, both highly experienced professionals in their respective
fields, to the Supervisory Board” said Dr. Thomas Hecht, Chairman
of Affimed’s Supervisory Board. “Annalisa is a visionary leader who
knows how to translate science from bench to bedside. Harry
is an accomplished financial executive who is well suited to help
drive value-creating strategies for the company. Together,
these new appointments position us to ensure sound corporate
governance by further strengthening our biotech industry know-how
and experience as well as our diversity.”
Dr. Jenkins, with more than 25 years of global
pharmaceutical experience, brings a wealth of expertise in
advancing clinical programs through development and to regulatory
approval. Dr. Jenkins serves on the Board of Directors for a number
of publicly and privately held biotechnology and life science
companies. In addition, she is a committee member of the science
board to the U.S. Food and Drug Administration (FDA), which advises
FDA leadership on complex scientific and technical issues.
Dr. Jenkins served as the Chief Executive Officer of
PlaqueTec Ltd. and Dimension Therapeutics. Prior leadership roles
held by Dr. Jenkins include Executive Vice President, Global
Research and Development at Merck Serono Pharmaceuticals as well
as several leadership positions at Bristol-Myers Squibb. Dr.
Jenkins graduated with a degree in medicine from St. Bartholomew’s
Hospital at the University of London and subsequently trained in
cardiovascular medicine in the UK National Health Service.
Mr. Welten brings significant financial and U.S.
market expertise to Affimed. He is chairman and member of the
board of directors of several biotechnology companies in
Switzerland, Germany and the U.S. Over the last 20 years, Mr.
Welten served as Chief Financial Officer of both public as well as
venture capital financed biotech companies. Mr. Welten has served
in senior roles at UBS in Switzerland and New York for the first 15
years of his career. Mr. Welten has degrees in Banking, Finance and
Economics as well as an MBA from Columbia University, NY, USA.
About Affimed N.V.
Affimed (Nasdaq: AFMD) is a clinical-stage
immuno-oncology company committed to giving patients back their
innate ability to fight cancer. Affimed’s fit-for-purpose ROCK®
platform allows innate cell engagers to be designed for specific
patient populations. The company is developing single and
combination therapies to treat hematologic and solid tumors. The
company is currently enrolling patients into a
registration-directed study of AFM13 for CD30-positive
relapsed/refractory peripheral T cell lymphoma and into a Phase
1/2a dose escalation/expansion study of AFM24 for the treatment of
advanced EGFR-expressing solid tumors. For more information, please
visit www.affimed.com.
FORWARD-LOOKING STATEMENTS
This press release contains forward-looking
statements. All statements other than statements of historical fact
are forward-looking statements, which are often indicated by terms
such as “anticipate,” “believe,” “could,” “estimate,” “expect,”
“goal,” “intend,” “look forward to,” “may,” “plan,” “potential,”
“predict,” “project,” “should,” “will,” “would” and similar
expressions. Forward-looking statements appear in a number of
places throughout this release and include statements regarding our
intentions, beliefs, projections, outlook, analyses and current
expectations concerning, among other things, the potential of
AFM24, the value of our ROCK® platform, our ongoing and planned
preclinical development and clinical trials, our collaborations and
development of our products in combination with other therapies,
the timing of and our ability to make regulatory filings and obtain
and maintain regulatory approvals for our product candidates, our
intellectual property position, our collaboration activities, our
ability to develop commercial functions, clinical trial data, our
results of operations, cash needs, financial condition, liquidity,
prospects, future transactions, growth and strategies, the industry
in which we operate, the trends that may affect the industry or us,
impacts of the COVID-19 pandemic, the benefits to Affimed of orphan
drug designation and the risks, uncertainties and other factors
described under the heading “Risk Factors” in Affimed’s filings
with the Securities and Exchange Commission. Given these risks,
uncertainties and other factors, you should not place undue
reliance on these forward-looking statements, and we assume no
obligation to update these forward-looking statements, even if new
information becomes available in the future.
Investor Contact
Alex Fudukidis
Head of Investor Relations
Email: IR@affimed.com
Tel: (917) 436-8102
Affimed NV (NASDAQ:AFMD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Affimed NV (NASDAQ:AFMD)
Historical Stock Chart
From Apr 2023 to Apr 2024